Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin Versus Placebo in CCUS, LR-MDS, and MPNs
NCT06063486Phase 2Recruiting
- Sponsor
- University of Southern California
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of curcumin in clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN) (2 arms), sponsored by University of Southern California. Primary endpoints: Mean change in peripheral blood levels of inflammatory cytokines at 12 months, Mean change in symptom scores for clonal cytopenia of undetermined significance and low risk myelodysplastic syndrome patients at 12 months and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
curcumin
03
Conditions
clonal cytopenia of undetermined significance (CCUS)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06063486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063486.